WILMINGTON, NC--(Marketwire - January 22, 2009) -
Gene Express Inc. announced today that it
has entered into a Distribution Agreement with Biogenuix Medsystems Pvt.
Ltd. for the distribution of Gene Express Inc's Standardized RT-PCR
(StaRT-PCR™) and research molecular diagnostic tools. The non-exclusive
agreement provides Biogenuix with the rights to distribute in India.
Jonathan Rowe PhD, Chief Operating Officer for Gene Express Inc., stated,
"This will be the first time that Gene Express' patented standardized gene
expression technology will be made widely available to Indian researchers.
By partnering with a valuable partner in Biogenuix, we are confident that
the Gene Express tests and reagents will be widely accepted in the Indian
Sundeep Amar, Director of Biogenuix Medsystems Pvt. Ltd., stated, "We are
very optimistic about the potential of StaRT-PCR™ in India. This is the
right time to enter the Indian molecular diagnostic & research market as
there is a rapid growth in the installation base of RT-PCR platforms in the
Among the StaRT-PCR™ based research molecular tools are kits for Chronic
Myelogenous Leukemia (bcr-abl), Lung Cancer Risk Prediction and
Inflammation/Rheumatoid Arthritis. The reagents include a selection of
more than six hundred StaRT-PCR™ internal standards.
About Biogenuix Medsystems Pvt. Ltd.
Biogenuix plays a key role as a marketer, market research & service
provider to scientific & healthcare companies and professionals by offering
unique solutions through its philosophy of innovation, quality,
dependability and consistency. Biogenuix has long-term distribution and
marketing agreements with more than 20 leading manufacturers of
diagnostics, life-sciences, biopharma products and International marketing
services companies. Biogenuix's portfolio includes a range of Specialized
Diagnostic products as well as a large portfolio of antibodies,
peptides,IHC slides, si-RNA's, microarray substrates and other regents.
Biogenuix offers the most comprehensive range of Transplant Diagnostics
products in India and exclusively represents One Lambda Inc, the pioneers
and global leaders in transplant diagnostics and research products.
About Gene Express, Inc.
Gene Express, Inc. is a molecular diagnostic company that integrates
personalized medicine into clinical care by enabling the generation of
standardized, comparable and quality controlled data for molecular
diagnostic testing. The Company's proprietary and patented StaRT-PCR™
(Standardized Reverse Transcription Polymerase Chain Reaction) platform
technology for measuring gene expression levels in cells, clinical biopsies
and blood is being used to develop proprietary molecular diagnostics and to
develop the molecular diagnostics capabilities of other companies. The
Company's $3 billion focus market for licensing and contract services
includes the drug development, academic and molecular diagnostics segments.
Additional information is available on the Company's website at
Any forecasts, plans, projections and other information contained in this
press release describing events or results that may occur in the future are
"forward-looking statements" as defined in the United States Private
Securities litigation Reform Act of 1995. Forward-looking statements are
subject to risks, uncertainties and important factors that are beyond the
control of the Company that could cause actual results and events to differ
materially from the results presently anticipated or projected. Readers
are cautioned not to place undue reliance on these forward-looking
statements and any such forward-looking statements are qualified in their
entirety by reference to this cautionary statement. All forward-looking
statements contained herein speak only as of the date of this release and
are based on current expectations. The Company disclaims any obligation to
update or revise any forward-looking statements.